205 related articles for article (PubMed ID: 38232985)
21. Immunotherapy in Gynecologic Cancers: Are We There Yet?
Pakish JB; Jazaeri AA
Curr Treat Options Oncol; 2017 Aug; 18(10):59. PubMed ID: 28840453
[TBL] [Abstract][Full Text] [Related]
22. Upcoming innovations in lung cancer immunotherapy: focus on immune checkpoint inhibitors.
Aspeslagh S; Marabelle A; Soria JC; Armand JP
Chin Clin Oncol; 2015 Dec; 4(4):48. PubMed ID: 26730760
[TBL] [Abstract][Full Text] [Related]
23. Insight into RNA-based Therapies for Ovarian Cancer.
Keyvani V; Mahmoudian RA; Mollazadeh S; Kheradmand N; Ghorbani E; Khazaei M; Saeed Al-Hayawi I; Hassanian SM; Ferns GA; Avan A; Anvari K
Curr Pharm Des; 2023; 29(34):2692-2701. PubMed ID: 37916491
[TBL] [Abstract][Full Text] [Related]
24. Immunity and immune suppression in human ovarian cancer.
Preston CC; Goode EL; Hartmann LC; Kalli KR; Knutson KL
Immunotherapy; 2011 Apr; 3(4):539-56. PubMed ID: 21463194
[TBL] [Abstract][Full Text] [Related]
25. Breast Cancer Vaccines: Disappointing or Promising?
Zhu SY; Yu KD
Front Immunol; 2022; 13():828386. PubMed ID: 35154149
[TBL] [Abstract][Full Text] [Related]
26. Translational landscape of glioblastoma immunotherapy for physicians: guiding clinical practice with basic scientific evidence.
Kreatsoulas D; Bolyard C; Wu BX; Cam H; Giglio P; Li Z
J Hematol Oncol; 2022 Jun; 15(1):80. PubMed ID: 35690784
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic vaccines for ovarian cancer.
Liao JB; Disis ML
Gynecol Oncol; 2013 Sep; 130(3):667-73. PubMed ID: 23800697
[TBL] [Abstract][Full Text] [Related]
28. Highlights of the 31st annual meeting of the Society for Immunotherapy of Cancer (SITC), 2016.
Gulley JL; Repasky EA; Wood LS; Butterfield LH
J Immunother Cancer; 2017 Jul; 5(1):55. PubMed ID: 28716068
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy: an alternative promising therapeutic approach against cancers.
Gupta SL; Basu S; Soni V; Jaiswal RK
Mol Biol Rep; 2022 Oct; 49(10):9903-9913. PubMed ID: 35759082
[TBL] [Abstract][Full Text] [Related]
30. Ovarian cancer immunotherapy: opportunities, progresses and challenges.
Liu B; Nash J; Runowicz C; Swede H; Stevens R; Li Z
J Hematol Oncol; 2010 Feb; 3():7. PubMed ID: 20146807
[TBL] [Abstract][Full Text] [Related]
31. A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.
Kandalaft LE; Chiang CL; Tanyi J; Motz G; Balint K; Mick R; Coukos G
J Transl Med; 2013 Jun; 11():149. PubMed ID: 23777306
[TBL] [Abstract][Full Text] [Related]
32. Immunotherapy in ovarian, endometrial and cervical cancer: State of the art and future perspectives.
Ventriglia J; Paciolla I; Pisano C; Cecere SC; Di Napoli M; Tambaro R; Califano D; Losito S; Scognamiglio G; Setola SV; Arenare L; Pignata S; Della Pepa C
Cancer Treat Rev; 2017 Sep; 59():109-116. PubMed ID: 28800469
[TBL] [Abstract][Full Text] [Related]
33. Current approaches in ovarian cancer vaccines.
Reinartz S; Wagner U
Minerva Ginecol; 2004 Dec; 56(6):515-27. PubMed ID: 15729204
[TBL] [Abstract][Full Text] [Related]
34. Immune Therapy Opportunities in Ovarian Cancer.
Kandalaft LE; Odunsi K; Coukos G
Am Soc Clin Oncol Educ Book; 2020 May; 40():1-13. PubMed ID: 32412818
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy targeting both innate and adaptive immunity improves survival in a pre-clinical model of ovarian cancer.
Hartl CA; Bertschi A; Puerto RB; Andresen C; Cheney EM; Mittendorf EA; Guerriero JL; Goldberg MS
J Immunother Cancer; 2019 Jul; 7(1):199. PubMed ID: 31362778
[TBL] [Abstract][Full Text] [Related]
36. Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer.
Dumitru A; Dobrica EC; Croitoru A; Cretoiu SM; Gaspar BS
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36292922
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapeutic advances in gastric cancer.
Yoneda A; Kuroki T; Eguchi S
Surg Today; 2021 Nov; 51(11):1727-1735. PubMed ID: 33590326
[TBL] [Abstract][Full Text] [Related]
38. Combining immunotherapies for the treatment of prostate cancer.
Redman JM; Gulley JL; Madan RA
Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
[TBL] [Abstract][Full Text] [Related]
39. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
Madden DL
Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer immunotherapy: Current and novel approaches.
Barzaman K; Moradi-Kalbolandi S; Hosseinzadeh A; Kazemi MH; Khorramdelazad H; Safari E; Farahmand L
Int Immunopharmacol; 2021 Sep; 98():107886. PubMed ID: 34153663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
